NIFTY:
The NIFTY opened at 19744.85 without much of a gap. The index initially moved up but soon found resistance and turned down. A sharp decline came that led prices towards 17950. The index found support there and started moving higher. Soon prices broke above early morning highs but could not sustain there longer and saw another leg of decline. The NIFTY recorded its intraday high at 19798.65 in the afternoon, its intraday low at 19657.50 towards the end, and finally closed at 19674.25 with a loss of 68.10 points or 0.34% down. All the sectoral indices moved in line with the NIFTY 50 index and closed in red except AUTO which ended with marginal gains. PHARMA led the bears today and ended with a loss of 1.55%. Resistance is visible around 20200 while support is visible around 19700. The index is now moving around the support levels.
BANK NIFTY:
The BANK NIFTY opened at 44707.35 with a gap up of 97 points. The index initially moved higher but soon drifted downwards. Prices have erased all the gains and then again turned around and moved higher. That volatile movement continued for the whole day. In this process, prices have recorded its intraday high at 44996.75, its intraday low at 44548.90, and finally closed at 44639.95 with a gain of just 19 points. PSU BANK has significantly outperformed, saw a sharp upside move, and closed with a gain of 3.51%. PVT BANK has underperformed, saw a mild down move, and ended with a loss of 0.09%. Within the index, in terms of points, INDUSIND BANK contributed the highest on the upside while HDFC BANK contributed the least. The short-term trend is sideways. A sharp decline seems to now finding support around 44600 while resistance is visible around 46200. On the weekly timeframe chart, the index has been consolidating for the past four months within a wide range of 43600-46300. The current week was a big bearish candle so it is possible that the next week may be narrow and choppy.
TECHNICAL PICKS
COMPANY NAME | CMP | B/S | RATIONALE |
ASIAN PAINT | 3274.85 | BUY | The stock is about to give a breakout on the intraday and the daily chart. The stock can be bought above 3274.85 with a stop loss of 3208.50 and a target of 3413.50. |
INDIGO | 2355.55 | SELL | The stock has given a breakdown on the intraday as well as the daily chart. The stock can be sold below 2355.55 with a stop loss of 2395.00 and a target of 2272.00. |
DERIVATIVE PICKS
Stock Name | Strike Price | Buy/Sell | CMP | Initiation | Stop Loss | Target | Remarks |
TATA CONSUMER | 880 CE | BUY | 7.50 | CMP | 5.95 | 12.20 | BREAKOUT |
Long Buildup | Short Buildup | |||||||||
Stocks | Price | Price% | OI % | OI | Stocks | Price | Price% | OI % | OI | |
GRANULES.23.09 Sep | 337.8 | 4.29 | 3.07 | 10662000 | DALBHARAT.23.09 Sep | 2254.05 | -0.9 | 1.32 | 1263000 | |
Short Covering | Long Unwinding | |||||||||
Stocks | Price | Price% | OI % | OI | Stocks | Price | Price% | OI % | OI | |
CANBK.23.09 Sep | 383.2 | 5.17 | -4.65 | 43308000 | NAUKRI.23.09 Sep | 4293.35 | -3.31 | -4.75 | 1409700 | |
BERGEPAINT.23.09 Sep | 619.7 | 4.72 | -8.02 | 10717080 | ZYDUSLIFE.23.09 Sep | 596.75 | -3.14 | -7.28 | 5391000 | |
RECLTD.23.09 Sep | 271.55 | 4.5 | -4.68 | 46088000 | GLENMARK.23.09 Sep | 803.95 | -3.13 | -5 | 8466550 | |
IDEA.23.09 Sep | 11.35 | 4.13 | -13.94 | 941520000 | ALKEM.23.09 Sep | 3549.3 | -2.8 | -4.13 | 755800 | |
BANKBARODA.23.09 Sep | 215.8 | 4.13 | -9.25 | 85837050 | ASTRAL.23.09 Sep | 1836.85 | -2.67 | -4.56 | 3506318 |
Top Delivery Percentage
Stocks | Price | %Chg | Total Qty | Delivery | Del % | % Change | ||||
Sectors | Price | Change % | Quantity | |||||||
Torrent Pharma Ltd. | 1850.4 | -1.28 | 498682 | 318995 | 82.64 | Nifty50 | 19674.25 | -0.34 | 37252317 | |
Alkem | 3550.65 | -2.77 | 267533 | 106263 | 72.52 | Niftybank | 44612.05 | -0.03 | 16425079 | |
Dabur India Ltd. | 561.3 | 0.21 | 956641 | 1523608 | 70.86 | Nifty it | 32906.3 | -0.04 | 924252 | |
Pidilite Industries Ltd | 2517.7 | 0.19 | 348380 | 188506 | 67.4 | India Vix | 10.66 | -1.48 | 680145752 | |
Sbi Cards And Payment Se | 798.4 | -0.2 | 2053947 | 912005 | 66.8 | Nifty Fmcg | 51608.5 | -0.12 | 297351 | |
Cummins India Limited | 1725.35 | -1.11 | 418784 | 376802 | 65.62 | Nifty Pharma | 15069.1 | -1.55 | 48392888 | |
Indigo | 2355.55 | -1.32 | 702509 | 458730 | 64.24 | Nifty Realty | 561.5 | -0.66 | 1300258731 | |
Hindustan Unilever Ltd | 2482.45 | 0.37 | 1176741 | 1423652 | 64.02 | Nifty Auto | 16234.35 | 0.21 | 45225129 | |
Marico Limited | 573.9 | -0.13 | 871842 | 461438 | 63.29 | Nifty Metal | 6761.8 | -0.66 | 108218240 | |
Syngene | 771.45 | -0.8 | 922159 | 884344 | 63.16 | Nifty Financial Services | 19732.95 | -0.41 | 5861137 |
Upcoming Economic Data
Domestic International | |
INR: FX Reserves, USD on 29th September, 2023
INR: Infrastructure Output (YoY) (Aug) on 29th September, 2023 |
USD: Building Permits on 26th September, 2023
USD: New Home Sales (Aug) on 26th September, 2023 |
News Updates
-
Indices extend losses to fourth session after volatile trade, Nifty ends below 19,700. The Sensex was down 221.09 points or 0.33 percent at 66,009.15, and the Nifty was down 68.00 points or 0.34 percent at 19,674.30. About 1747 shares advanced, 1779 shares declined, and 143 shares unchanged.
-
Shares of PNB Gilts hit 20 percent upper circuit on September 22 to hit Rs 81 per share on BSE in intra-day trade on the back of heavy volumes, as India’s inclusion in JPMorgan’s bond index is seen driving billion of dollars of inflows. The stock also breached its previous 52-week high of Rs 71.6 apiece touched on July 21, 2023.
-
The pharmaceutical sector is exhibiting strong bearish positions on September 22. Among individual stocks in the sector, short positions can be observed in Glenmark, Cipla, Alkem and Dr Reddy’s for the day.
-
Banking stocks in India remain the preferred pick for JP Morgan on expectation of strong earnings growth in the sector, said Sanjay Mookim, JP Morgan’s Head of Research. “In terms of combination of growth and value, banks look good in India,” said Mookimin in a panel interview with CNBC TV18.
Source: Economic Times, Indian Express, Business Today, Livemint, Business Standard, Bloomberg Quint
Board Meetings
Company Name | Purpose | Meeting Date | Company Name | Purpose | Meeting Date |
ANKITMETAL | General | 25-Sep-23 | CANFINHOME | General | 27-Sep-23 |
AVANCE | General;Increase in Authorised Capital;Stock Split | 25-Sep-23 | HDIL | Quarterly Results | 27-Sep-23 |
INFRAIND | Audited Results | 25-Sep-23 | INFRAIND | General | 27-Sep-23 |
INTECCAP | General | 25-Sep-23 | KAARYAFSL | General | 27-Sep-23 |
JYOTISTRUC | General | 25-Sep-23 | KINGSINFR | General | 27-Sep-23 |
MADHUVEER | Preferential Issue of shares | 25-Sep-23 | RITCO | Employees Stock Option Plan;General;Issue Of Warrants | 27-Sep-23 |
MANGIND | General | 25-Sep-23 | LORDSHOTL | General | 28-Sep-23 |
POWERGRID | General | 25-Sep-23 | DILIGENT | A.G.M. | 29-Sep-23 |
RATNAVEER | Quarterly Results | 25-Sep-23 | VAICC | A.G.M. | 29-Sep-23 |
ROYALCU | Issue Of Warrants;Preferential Issue of shares | 25-Sep-23 | AAPLUSTRAD | A.G.M. | 30-Sep-23 |
SFL | General | 25-Sep-23 | INTETHR | A.G.M. | 30-Sep-23 |
SPANDANA | General | 25-Sep-23 | GOODLUCK | Issue Of Warrants | 03-Oct-23 |
STAR | Scheme of Arrangement | 25-Sep-23 | KRRAIL | General | 03-Oct-23 |
STARHFL | General | 25-Sep-23 | HCLTECH | Interim Dividend;Quarterly Results | 12-Oct-23 |
STRLGUA | General | 25-Sep-23 | HDFCAMC | Quarterly Results | 12-Oct-23 |
VEERHEALTH | Bonus issue | 25-Sep-23 | INFY | Interim Dividend;Audited Results | 12-Oct-23 |
VPRPL | Quarterly Results | 25-Sep-23 | KSOLVES | Interim Dividend;Quarterly Results | 15-Oct-23 |
WARDWIZFBL | General | 25-Sep-23 | ZENSARTECH | Quarterly Results | 17-Oct-23 |
CORALAB | General | 26-Sep-23 | PERSISTENT | General;Quarterly Results | 18-Oct-23 |
TAPARIA | General | 26-Sep-23 | COFORGE | Interim Dividend;Quarterly Results | 19-Oct-23 |
VINNY | Increase in Authorised Capital;Right Issue of Equity Shares | 26-Sep-23 | MPHASIS | Quarterly Results | 19-Oct-23 |
ZUARIIND | General | 26-Sep-23 | ULTRACEMCO | Quarterly Results | 19-Oct-23 |
Corporate Action
Company Name | Ex-Date | Purpose | Company Name | Ex-Date | Purpose |
BPLPHARMA | 25-Sep-23 | Final Dividend – Rs. – 0.7500 | HPIL | 29-Sep-23 | Final Dividend – Rs. – 0.5000 |
INDXTRA | 25-Sep-23 | Stock Split From Rs.10/- to Rs.1/- | MAHSCOOTER | 29-Sep-23 | Interim Dividend – Rs. – 110.0000 |
INFRAIND | 25-Sep-23 | Resolution Plan -Suspension | SINCLAIR | 29-Sep-23 | Buy Back of Shares |
NATPEROX | 25-Sep-23 | Spin Off | ACCELYA | 06-Oct-23 | Final Dividend – Rs. – 30.0000 |
TECHIN | 25-Sep-23 | E.G.M. | SIGACHI | 09-Oct-23 | Stock Split From Rs.10/- to Rs.1/- |
SHRADHAIND | 26-Sep-23 | Stock Split From Rs.10/- to Rs.5/- | HCLTECH | 20-Oct-23 | Interim Dividend |
SEMAC | 27-Sep-23 | Final Dividend – Rs. – 5.0000 | SVRL | 27-Oct-23 | Bonus issue 1:1 |
WESTLEIRES | 27-Sep-23 | Dividend – Rs. – 0.1000 | ASIANPAINT | 03-Nov-23 | Interim Dividend |
BAJAJHLDNG | 29-Sep-23 | Interim Dividend – Rs. – 110.0000 | PGHL | 13-Nov-23 | Final Dividend – Rs. – 50.0000 |
HAL | 29-Sep-23 | Stock Split From Rs.10/- to Rs.5/- | PGHH | 17-Nov-23 | Final Dividend – Rs. – 105.0000 |
Disclosure in pursuance of Section 19 of SEBI (RA) Regulation 2014
Elite Wealth Limited does/does not do business with companies covered in its research reports. Investors should be aware that the Elite Wealth Limited may/may not have a conflict of interest that could affect the objectivity of this report. Investors should consider this report as only information in making their investment decision and must exercise their own judgment before making any investment decision.
For analyst certification and other important disclosures, see the Disclosure Appendix, or go to www.elitewealth.in. Analysts employed by Elite Wealth Limited are registered/qualified as research analysts with SEBI in India.( SEBI Registration No.: INH100002300)
Disclosure Appendix
Analyst Certification (For Reports)
Kiran Tahlani, Elite Wealth Limited, kirantahlani@elitestock.com
The analyst(s) certify that all of the views expressed in this report accurately reflect my/our personal views about the subject company or companies and its or their securities. I/We also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report. Unless otherwise stated, the individuals listed on the cover page of this report are analysts in Elite Wealth Limited.
As to each individual report referenced herein, the primary research analyst(s) named within the report individually certify, with respect to each security or issuer that the analyst covered in the report, that:
(1) all of the views expressed in the report accurately reflect his or her personal views about any and all of the subject securities or issuers; and
(2) no part of any of the research analyst’s compensation was, is, or will be directly or indirectly related to the specific recommendations or views expressed in the report.
For individual analyst certifications, please refer to the disclosure section at the end of the attached individual notes.
Research Excerpts
This note may include excerpts from previously published research. For access to the full reports, including analyst certification and important disclosures, investment thesis, valuation methodology, and risks to rating and price targets, please visit www.elitewealth.in.
Company-Specific Disclosures
Important disclosures, including price charts, are available and all Elite Wealth Limited covered companies by visiting https://www.elitewealth.in, or e-mailing research@elitestock.com with your request. Elite Wealth Limited may screen companies based on Strategy, Technical, and Quantitative Research. For important disclosures for these companies, please e-mail research@elitestock.com.
Options related research:
If the information contained herein regards options related research, such information is available only to persons who have received the proper option risk disclosure documents. For a copy of the risk disclosure documents, please contact your Broker’s Representative or visit the OCC’s website at https://www.elitewealth.in
Other Disclosures
All research reports made available to clients are simultaneously available on our client websites. Not all research content is redistributed, e-mailed or made available to third-party aggregators. For all research reports available on a particular stock, please contact your respective broker’s sales person.
Ownership and material conflicts of interest Disclosure
Elite Wealth Limited policy prohibits its analysts, professionals reporting to analysts from owning securities of any company in the analyst’s area of coverage. Analyst compensation: Analysts are salary based permanent employees of Elite Wealth Limited. Analyst as officer or director: Elite Wealth Limited policy prohibits its analysts, persons reporting to analysts from serving as an officer, director, board member or employee of any company in the analyst’s area of coverage.
Country Specific Disclosures
India – For private circulation only, not for sale.
Legal Entities Disclosures
Mr. Ravinder Parkash Seth is the Managing Director of Elite Wealth Ltd (EWL, henceforth), having its registered office at Casa Picasso, Golf Course Extension, Near Rajesh Pilot Chowk, Radha Swami, Sector-61, Gurgaon-122001 Haryana, is a SEBI registered Research Analyst and is regulated by Securities and Exchange Board of India. Telephone: 011-43035555, Facsimile: 011-22795783 and Website: www.elitewealth.in
EWL discloses all material information about itself including its business activity, disciplinary history, the terms and conditions on which it offers research report, details of associates and such other information as is necessary to take an investment decision, including the following:
- Reports
- a) EWL or his associate or his relative has no financial interest in the subject company and the nature of such financial interest;
(b) EWL or its associates or relatives, have no actual/beneficial ownership of one per cent. or more in the securities of the subject company, at the end of the month immediately preceding the date of publication of the research report or date of the public appearance;
(c) EWL or its associate or his relative, has no other material conflict of interest at the time of publication of the research report or at the time of public appearance;
- Compensation
(a) EWL or its associates have not received any compensation from the subject company in the past twelve months;
(b) EWL or its associates have not managed or co-managed public offering of securities for the subject company in the past twelve months;
(c) EWL or its associates have not received any compensation for investment banking or merchant banking or brokerage services from the subject company in the past twelve months;
(d) EWL or its associates have not received any compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past twelve months;
(e) EWL or its associates have not received any compensation or other benefits from the subject company or third party in connection with the research report.
3 In respect of Public Appearances
(a) EWL or its associates have not received any compensation from the subject company in the past twelve months;
(b) The subject company is not now or never a client during twelve months preceding the date of distribution of the research report and the types of services provided by EWL
Provided that research analyst or research entity shall not be required to make a disclosure as per sub-clauses (c), (d) and (e) of clause (ii) or sub-clauses (a) and (b) of clause (iii) to the extent such disclosure would reveal material non-public information regarding specific potential future investment banking or merchant banking or brokerage services transactions of the subject company.
(4) EWL or its proprietor has never served as an officer, director or employee of the subject company;
(5) EWL has never been engaged in market making activity for the subject company;
(6) EWL shall provide all other disclosures in research report and public appearance as specified by the Board under any other regulation